Goldman Sachs’s Cellectis CLLS Stock Holding History

Goldman Sachs’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,208	Closed	-$38.2K	–	5950
2022 Q4	$38.2K	Buy	+18,208	New	+$41.3K	﹤0.01%	5631
2022 Q2	–	Sell	-53,223	Closed	-$242K	–	6485
2022 Q1	$242K	Buy	+53,223	New	+$293K	﹤0.01%	5776
2021 Q1	–	Sell	-67,076	Closed	-$1.81M	–	6104
2020 Q4	$1.81M	Buy	67,076 +28,642	+75%	+$643K	﹤0.01%	3801
2020 Q3	$711K	Buy	+38,434	New	+$682K	﹤0.01%	4293
2020 Q2	–	Sell	-19,828	Closed	-$182K	–	5234
2020 Q1	$182K	Buy	+19,828	New	+$296K	﹤0.01%	4741
2019 Q4	–	Sell	-31,268	Closed	-$325K	–	5228
2019 Q3	$325K	Buy	+31,268	New	+$420K	﹤0.01%	4651
2019 Q2	–	Sell	-25,278	Closed	-$464K	–	5152
2019 Q1	$464K	Buy	25,278 +11,838	+88%	+$210K	﹤0.01%	4450
2018 Q4	$224K	Buy	+13,440	New	+$312K	﹤0.01%	4770
2016 Q1	–	Sell	-58,162	Closed	-$1.8M	–	7100
2015 Q4	$1.8M	Buy	+58,162	New	+$1.76M	﹤0.01%	3725

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Goldman Sachs's CLLS Position: Q1 2023 in Review

Goldman Sachs sold out of Cellectis (CLLS) in Q1 2023, closing a stake of 18,208 shares — an estimated $38.2K sold.

Goldman Sachs first reported a position in CLLS in Q4 2015 and held it in 9 quarters. The position peaked at $1.81M in Q4 2020. 34 funds tracked by Wall St. Rank hold CLLS as of Q1 2023.

Goldman Sachs reported no remaining Cellectis position as of Q1 2023 after selling out during the quarter.
Goldman Sachs sold 18,208 Cellectis shares in Q1 2023, an estimated $38.2K.
Goldman Sachs first reported a position in Cellectis in Q4 2015 and held it in 9 quarters.
Goldman Sachs's Cellectis position peaked at $1.81M in Q4 2020.
34 funds tracked by Wall St. Rank held Cellectis as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.